Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897319669> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2897319669 endingPage "e692" @default.
- W2897319669 startingPage "e692" @default.
- W2897319669 abstract "The efficacy of third-line or beyond chemotherapy in advanced non-small cell lung cancer (NSCLC) patients is low. Apatinib, as a novel small molecule antiangiogenic drug, has demonstrated satisfactory anticancer activity across a broad range of malignancies. The aim of this study is to evaluate the efficacy and safety of apatinib alone or combined with radiotherapy in patients with advanced NSCLC after second-line or beyond treatment failure. This study comprised 81 patients with advanced NSCLC who had progressed after second-line or beyond treatment. Patients received apatinib alone or combined with radiotherapy between August 2015 and November 2017. Survival and toxicities outcome were evaluated by Kaplan-Meier method and according to NCI-CTC4.0. After dose adjustment, 59 patients (72.8%) received 500 mg daily of apatinib, 12 patients received 250mg, and 10 received 425mg daily. 44(54.3%) patients received apatinib alone and 37(45.7%) patients received apatinib combined with radiotherapy to primary tumor or metastatic sites. The median progression free survival (PFS) and overall survival (OS) was 5.9 (95% CI:4.6-7.2） and 10.8 (95% CI: 9.4-12.1) months. Compared with apatinib alone, the median PFS in patients with apatinib combined with radiotherapy were 4.2 and 7.4 months (P=0.01), respectively. The median OS in apatinib monotherapy and apatinib combined with radiotherapy were 8.9 and 11.3 months (P=0.47), respectively. The incidence of adverse events in grades 3-4 were 24.7%. The most common adverse events in this study were hypertension(40.7%), hand-foot syndrome(35.8%), fatigue (27.1%), proteinuria(25.9%), gastrointestinal toxicity (22.2%) , hemorrhage (12.3%) and mouth mucositis (11.1%). Apatinib alone or combined with radiotherapy is efficacious in treating patients with advanced NSCLC after two or more lines of treatment failure, with acceptable toxic effects." @default.
- W2897319669 created "2018-10-26" @default.
- W2897319669 creator A5005940399 @default.
- W2897319669 creator A5012189788 @default.
- W2897319669 creator A5016098560 @default.
- W2897319669 creator A5044248949 @default.
- W2897319669 creator A5044937746 @default.
- W2897319669 creator A5058868917 @default.
- W2897319669 creator A5075086137 @default.
- W2897319669 creator A5077845197 @default.
- W2897319669 date "2018-11-01" @default.
- W2897319669 modified "2023-09-27" @default.
- W2897319669 title "Apatinib Alone or Combined with Radiation Therapy As a Salvage Treatment in Advanced Non-Small Cell Lung Cancer Failed from Two or More Lines of Prior Chemotherapy or Molecular Targeted Therapy" @default.
- W2897319669 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1863" @default.
- W2897319669 hasPublicationYear "2018" @default.
- W2897319669 type Work @default.
- W2897319669 sameAs 2897319669 @default.
- W2897319669 citedByCount "0" @default.
- W2897319669 crossrefType "journal-article" @default.
- W2897319669 hasAuthorship W2897319669A5005940399 @default.
- W2897319669 hasAuthorship W2897319669A5012189788 @default.
- W2897319669 hasAuthorship W2897319669A5016098560 @default.
- W2897319669 hasAuthorship W2897319669A5044248949 @default.
- W2897319669 hasAuthorship W2897319669A5044937746 @default.
- W2897319669 hasAuthorship W2897319669A5058868917 @default.
- W2897319669 hasAuthorship W2897319669A5075086137 @default.
- W2897319669 hasAuthorship W2897319669A5077845197 @default.
- W2897319669 hasBestOaLocation W28973196691 @default.
- W2897319669 hasConcept C121608353 @default.
- W2897319669 hasConcept C126322002 @default.
- W2897319669 hasConcept C141071460 @default.
- W2897319669 hasConcept C143998085 @default.
- W2897319669 hasConcept C197934379 @default.
- W2897319669 hasConcept C2776256026 @default.
- W2897319669 hasConcept C2776694085 @default.
- W2897319669 hasConcept C2780668389 @default.
- W2897319669 hasConcept C509974204 @default.
- W2897319669 hasConcept C71924100 @default.
- W2897319669 hasConceptScore W2897319669C121608353 @default.
- W2897319669 hasConceptScore W2897319669C126322002 @default.
- W2897319669 hasConceptScore W2897319669C141071460 @default.
- W2897319669 hasConceptScore W2897319669C143998085 @default.
- W2897319669 hasConceptScore W2897319669C197934379 @default.
- W2897319669 hasConceptScore W2897319669C2776256026 @default.
- W2897319669 hasConceptScore W2897319669C2776694085 @default.
- W2897319669 hasConceptScore W2897319669C2780668389 @default.
- W2897319669 hasConceptScore W2897319669C509974204 @default.
- W2897319669 hasConceptScore W2897319669C71924100 @default.
- W2897319669 hasIssue "3" @default.
- W2897319669 hasLocation W28973196691 @default.
- W2897319669 hasOpenAccess W2897319669 @default.
- W2897319669 hasPrimaryLocation W28973196691 @default.
- W2897319669 hasRelatedWork W1975025425 @default.
- W2897319669 hasRelatedWork W2112851763 @default.
- W2897319669 hasRelatedWork W2277416945 @default.
- W2897319669 hasRelatedWork W2357406576 @default.
- W2897319669 hasRelatedWork W2360529269 @default.
- W2897319669 hasRelatedWork W2375646327 @default.
- W2897319669 hasRelatedWork W2378022161 @default.
- W2897319669 hasRelatedWork W2413020017 @default.
- W2897319669 hasRelatedWork W2418514417 @default.
- W2897319669 hasRelatedWork W1899415052 @default.
- W2897319669 hasVolume "102" @default.
- W2897319669 isParatext "false" @default.
- W2897319669 isRetracted "false" @default.
- W2897319669 magId "2897319669" @default.
- W2897319669 workType "article" @default.